Sanofi’s Tzield has been accepted for priority review by the U.S. Food and Drug Administration to expand its use to children aged one year and older with stage 2 type 1 diabetes. The submission is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback